Beibei Ding

Beibei Ding has an extensive work experience in the field of cell therapy, gene editing, and cell biology.

They currently hold the position of Principal Scientist at Adicet Bio, Inc since September 2022.

Prior to that, they worked at Thermo Fisher Scientific as a Scientist III in the Gene Editing department from July 2022 to August 2022.

From 2016 to 2022, Beibei served at Sorrento Therapeutics, Inc. in various roles, including Director of Cell Therapy from March 2020 to April 2022, Associate Director of Cell Therapy from January 2018 to March 2020, and Scientist in Cell Therapy from November 2016 to December 2017. During their time at Sorrento Therapeutics, they led the KOKI CAR-T R&D team and contributed to the identification, evaluation, and development of novel CAR-T/DAR-T/Bi-specific CAR-T candidates. They also designed models to support the testing of anti-tumor efficacy, CAR-T/DAR-T safety, and allograft rejection.

From 2013 to 2016, Beibei worked as a Cell Biology Scientist at BioLegend. Their responsibilities included setting up cell and lysate banks, evaluating new antibodies, and collaborating with other groups to develop new products.

Prior to that, they held the position of Senior Scientist at the University of Kansas Medical Center from February 2009 to March 2011, working in the lab of Prof. Joan Hunt.

Beibei also worked as a Postdoctoral Research Fellow at Albert Einstein College of Medicine from May 2003 to February 2009, where they conducted research on BCL6, a transcriptional repressor, and its targets in diffuse Large B cell Lymphoma (DLBCL) and primary B cells. They developed a system for germinal center-like B cell line differentiation and isolated primary central blast cells from human tonsils.

Before their time at Albert Einstein College of Medicine, Beibei worked as a Postdoctoral Research Fellow at Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences from July 2001 to May 2003. They conducted research on the roles of Neuronal Migratory Cue Slit2 in tumor growth and metastasis and prepared monoclonal and polyclonal antibodies against Robo1 and Slit2.

Beibei Ding has an extensive education history in the field of medicine. Beibei started their academic journey in 1989 at Nanjing Medical College, where they pursued a degree in Clinical Medicine. Beibei completed their MD equivalent degree in 1992.

Motivated to deepen their knowledge and expertise, Beibei enrolled at the Medical College of Southeast University from 1995 to 1998. During this period, they obtained a Master's degree in Histology and Embryology.

Continuing their educational pursuits, Beibei Ding later joined the Shanghai Medical College of Fudan University from 1998 to 2001. Here, they achieved a Ph.D. in Anatomy & Histology and Embryology, further specializing in their field of study.

In addition to their formal education, Beibei underwent professional development by obtaining a certification in "Leadership: Practical Skills" from LinkedIn in May 2022.

These experiences demonstrate Beibei Ding's dedication and extensive academic background in the medical field, providing their with a strong foundation and expertise in anatomy, histology, embryology, and clinical medicine.